Key Takeaways
- Revenue growth held up, but profitability slid: Consolidated revenue grew close to 18% YoY, yet EBITDA margins contracted as MTM forex losses of ~₹14 Cr and a delayed procurement-cost benefit hit the quarter.
- The US story is a tale of delays, not demand destruction: Two product approvals slipped, Brinzolamide profit share is yet to book, and a year-end dispatch freeze depressed sequential revenue, but management held its FY23 US guidance at ₹280–285 Cr.
- India business is stable but its mix is shifting: India grew 13% despite weak respiratory/anti-infective seasons, supported by sub-chronic therapies; its contribution to topline hit a multi-quarter low as international outgrew it.
- A fresh FDA overhang arrived: Plant-I in Goa received nine 483 observations post-inspection; current US supplies from the site are minimal, but the observations create uncertainty around future product approvals.
- What to watch next quarter: Whether Brinzolamide profit share actually books, the pace of resolution on the nine FDA observations, and if the promised Q4 procurement-cost benefits materialize in margins.
US Business: Delays, Profit Shares & the FDA Overhang
- Sequential dip is a timing issue, not a share loss: US rupee revenue declined sequentially because frontend partners closed from 18 December to 5 January for the holidays, and every dispatch to regulated markets needs documented partner approval; management expects a Q4 bounce-back.
- Two product approvals slipped: A modified-release cardiac product and one other important product were postponed, pushing substantial revenue into the next financial year; management held FY23 guidance at ₹280–285 Cr despite the delays.
- Brinzolamide profit share remains elusive: No profit share booked YTD in FY23 because the largest filled-volume strength has not yet sold in the US, and both Indoco and Teva have been "exceedingly over careful" on container closure system issues; real returns are yet to come from both sale and margin.
- Combigan profit share is a FY24 event: Combigan launched in mid-to-late October with over six weeks of revenue in Q3, but profit share will only arrive in FY24 due to the lag between product transfer and partner sale.
- A delayed milestone with Teva: A milestone of ~₹10 Cr from an unnamed partnered product was due before 31 December but got delayed into April; management called these "dynamic factors beyond our control" but asserted firm control of the business.
- FDA observations create an approval overhang: Plant-I in Goa received nine 483 observations; current US supplies from the site are minimal at ~₹6 Cr YTD, so near-term revenue is not threatened, but resolution is needed to unlock future approvals, including products filed from the site that go off patent after 2026–28.
- Ophthalmic regulation is a net positive: The FDA treating ophthalmics as medical devices regarding container closure systems protects manufacturers like Indoco because any container closure changes must now go through a regulatory pathway, preventing unreported changes that previously impacted product quality.
Aditi Panandikar: "...we bent backwards on account of that both Teva and us have been exceedingly over careful in supplying product to the US market. That has resulted in a delay in supply of a particular strength and that is why when you look at Brinzolamide, you look at the whole market, when we say the supply and sale has started, it is actually in the smaller market. So, the real returns are yet to come from both sale as well as margin."
Margin Walk: MTM, Mix & the Procurement Promise
- MTM forex losses of ~₹14 Cr hit the quarter: A substantial swing in the British pound and euro created notional mark-to-market losses that dragged other operating income and profitability.
- Gross margins have been sliding structurally: Excluding forex, gross margins fell from ~71% in FY21 to ~69.5% in FY22 to ~68% in FY23 9M, driven by a lower India contribution to topline, US investments yet to deliver returns, low-margin European contract manufacturing, and shrinking licensing-out income.
- Procurement cost benefits are just beginning to arrive: Benefits from API, packaging material, and equipment procurement were delayed but started flowing at end-December/early-January; the material effect is "quite substantial" and will largely be seen from Q4 FY23 onwards.
- Standalone EBITDA ex-other operating income was ~18%: This compares to 18.4% in the same quarter last year (which was reported as 21% with other operating income included); management expects improvement in Q4, typically a big quarter for high-margin India and emerging markets.
- Out-licensing income is shrinking by design: Indoco now prefers to retain IP rather than license it out, so dossier sale and licensing income has intentionally shrunk; management believes this delivers better long-term returns from the portfolio despite the near-term margin headwind.
Aditi Panandikar: "Indoco today would prefer to keep the IP for ourselves. So, this is the kind of an intended kind of a shrinkage of service income which as you know is much higher margins in the commercial space, but over a period of time we will get much better returns from this portfolio."
India Business: Steady Growth with a Shifting Mix
- 13% growth despite seasonal headwinds: Respiratory and anti-infectives, key India segments, did not contribute greatly in Q3; growth was supported by sub-chronic therapies like Stomatological, GI, and Vitamins/Minerals/Nutrients.
- New products are adding value: Noxa maintains its position as market leader in the Ozenoxacin segment, while Dropizin and Subitral continue to contribute.
- India contribution to topline hit a multi-quarter low: Q3 revenue of ₹203 Cr was almost equivalent to Q2, which historically never happens, driven by changing product mix and reduced product seasonality contribution to wholesale.
- FY23 India revenue on track for ~₹830 Cr: Management expects Q4 at ~₹220 Cr despite it being the seasonally weakest quarter, with product seasonality contribution to wholesale having come down.
- Digital initiatives target per-man profitability: Field sales officers have been given Apple iPads for detailing to doctors, and call-to-call reporting with MIS is expected to improve per-man returns and India business profitability over time.
Europe: Steady Growth, Tender Wins & Manufacturing Shifts
- Strong sequential growth of ~15%: Driven by good demand across Germany, Spain, and the UK for both traditional and new products.
- Allopurinol Germany tender renewed for two years: Indoco won the tender covering 90.5% of the total market, valued at ~₹65–70 Cr per year; supplies continued into January 2023 under the old contract.
- 20% Europe growth is a "done thing": Management expressed confidence in 20% growth for Europe, supported by various initiatives in next year's budget and applications for two more tenders where backward integration into APIs provides an edge.
- Manufacturing shifting to Baddi for efficiency: High-growth, voluminous European products are being transferred to Baddi I and III for larger batch sizes and better efficiency, freeing Goa capacity for higher-value US production.
- Paracetamol supply stabilized: Post-COVID stocking and supply issues are behind; consistent demand and a six-month rolling plan with partner Perrigo ensures no concerns.
Capacity, CAPEX & the Path to ₹5,000 Crores
- ₹5,000 Cr aspirational topline target by FY27–28: Management described it as a "big hairy audacious goal" but declined to give an exact geographic contribution split, saying "let us surprise you a bit."
- ~₹300 Cr CAPEX planned to support US growth: Includes adding packing lines at the sterile unit and planning a second sterile site on the drawing board; management will not wait and lose opportunity because building and approving a plant takes time.
- Goa solid oral capacity sufficient until US reaches ~₹1,500 Cr: Lower-margin European manufacturing is being moved to Baddi to free Goa capacity for the US; no further capacity addition is expected for Europe.
- ROCE target of 15% by the time topline hits ₹5,000 Cr: Up from the current ~13%; management noted that industry overall does roughly 11.9% close to 12% unless purely in India business where infrastructure investment is lower.
- CRO capacity expanded to ~150 beds: 48 beds added; with 60% of old capacity consumed internally, management is now more confident to generate external revenue from the expanded facility.
Aditi Panandikar: "Safe to say that we will ensure that even if India business does not contribute 50% of topline, the other business contributing largely to the topline which will be US, we will deliver on similar margins as India or more."
Quality & Regulatory: Observations as "Part of Business"
- Nine FDA 483 observations at Goa Plant-I: The audit concluded a few days before the call; management expressed confidence in the technical quality, compliance, and operations team to resolve the issues and further improve the quality management system.
- Observations are not expected to stop current supplies: YTD US supplies from the site were only ~₹6 Cr, so dependence is very low; even a prior warning letter did not stop manufacturing or supply from that site.
- One product likely lost on timing: Pregabalin capsules, filed from Plant-I, will likely be lost due to the FDA clearance delay, but several other products filed from the site going off patent after 2026–28 still have a window for approval.
- Sterile plant inspection expected soon: The FDA typically inspects Plant II/III every two years and has not come due to COVID; any improvement issues from Plant-I observations are being rolled out to all sites proactively.
Aditi Panandikar: "I think it is best on such calls to not give any assurance that we will come out clear or not... the number of SAR we file, the number of recall you do, all of that is an expression of a good quality management system. So, I feel confident that we are better able to manage quality than before, all the same when the auditors walk in. If there are any improvement issues, I am sure we will have observations. We should not be afraid of it."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US revenue | ₹280–285 Cr in FY23 despite two product approval delays | FY23 |
| Brinzolamide profit share | Likely to fall in Q4 FY23, but management noted a delay and expects profit shares to come in as and when sales happen | Q4 FY23 |
| Procurement cost benefits | Material effect to be seen largely from Q4 FY23 onwards | Q4 FY23 onwards |
| Europe growth | 20% growth, described as a "done thing" | Next year (FY24) |
| India revenue | Close to ₹830 Cr for FY23; Q4 at ~₹217 Cr | FY23 |
| CAPEX | Close to ₹300 Cr to support increased US share | Medium term (to ₹5,000 Cr topline) |
| ROCE | Improve from ~13% to 15% | By the time topline reaches ₹5,000 Cr |
| Topline aspiration | ₹5,000 Cr | FY27–28 |
| Allopurinol Germany tender | Supplies at ~₹65–70 Cr per year for the next 2 years | New 2-year contract |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Net revenue | ₹410.6 cr, +17.8% YoY vs ₹348.6 cr |
| Net revenue (9M FY23) | ₹1,210.10 cr, +9.8% YoY vs ₹1,102.4 cr |
| EBITDA to net sales | 15.0% at ₹61.7 cr vs 21.1% at ₹73.4 cr YoY |
| EBITDA without other operating income | 17.9% at ₹73.6 cr vs 18.4% at ₹64.3 cr YoY |
| PAT to net sales | 6.8% at ₹27.9 cr vs 9.5% at ₹33 cr YoY |
| Earnings per share | ₹3.03 vs ₹3.58 YoY |
| Domestic formulation revenue | ₹203.6 cr, +12.2% YoY vs ₹181.5 cr |
| International formulation revenue | ₹186.10 cr, +30.10% YoY vs ₹143 cr |
| US business revenue | ₹60.3 cr, +22.8% YoY vs ₹49.10 cr |
| Europe revenue | ₹86 cr, +58.5% YoY vs ₹54 cr |
| Regulated markets revenue | ₹151.7 cr, +39.5% YoY vs ₹108.7 cr |
| Emerging markets revenue | ₹34.4 cr, flat YoY |
| API business revenue | ₹16.2 cr vs ₹19.7 cr YoY |
| IPM rank and market share | 28th, market share of 0.67% |
| India business net price growth | 5–6% |
| US FY23 revenue guidance | ₹280–285 cr, revised from ~₹300 cr earlier |
| ROCE | 13% as on 31/12 vs 15% same time last year |
| Exchange fluctuation impact (net loss) | ₹14.03 cr in Q3, MTM and realized/unrealized |
| Allopurinol Germany tender annual value | ₹65–70 cr per year for next 2 years, 90.5% market share won |
| Pending US ANDA approvals | ~25 products across all sites, 10 own ANDAs |
| CRO capacity | ~150 beds after adding 48 beds to earlier ~98 |